Spots Global Cancer Trial Database for CCR5-blockade in Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CCR5-blockade in Metastatic Colorectal Cancer
Official Title: Treatment of Advanced Colorectal Cancer Patients With Hepatic Liver Metastases Using the CCR5-Antagonist Maraviroc (Phase I Maracon Trial)
Study ID: NCT01736813
Interventions
Study Description
Brief Summary: The surface molecule CCR5 is found on tumor cells within liver metastases of colorectal cancer. Inhibition of this molecule leads to a reduction in growth signals for tumor cells and subsequent slowed or halted tumor growth. The agent for the inhibition of CCR5 has already received FDA approval for treatment of HIV and has shown little side effects and toxicities even on long term treatment. Therefore CCR5-inhibition has the potential of providing non-toxic tumor growth inhibition.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg, Baden-Württemberg, Germany
Contact Details
Name: Niels Halama, MD
Affiliation: National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany
Role: PRINCIPAL_INVESTIGATOR
Name: Dirk Jaeger, MD
Affiliation: National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
